Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

N/A
3(100.0%)
3Total
N/A(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT04307836Not ApplicableUnknown

DENEX, Renal Denervation Therapy, in Patients With Hypertension on no or 1-3 Antihypertensive Medications

Role: lead

NCT04535050Not ApplicableRecruiting

DENEX Renal Denervation in Patients With Hypertension on no Antihypertensive Medications

Role: lead

NCT04248530Not ApplicableCompleted

DENEX Renal Denervation in Patients With Uncontrolled Hypertension: Safety Study

Role: lead

All 3 trials loaded